Search Results - "Looney, Cary M."

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics by Siegel, Michel, Steiner, Guido, Franssen, Linnea C, Carratu, Francesca, Herron, James, Hartman, Katharina, Looney, Cary M, Ducret, Axel, Bray-French, Katharine, Rohr, Olivier, Hickling, Timothy P, Smith, Noel, Marban-Doran, Céline

“…Immunogenicity, defined as the ability to provoke an immune response, can be either wanted (i.e., vaccines) or unwanted. The latter refers to an immune…”
Get full text

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics by Siegel, Michel, Padamsey, Aman, Bolender, Anna-Lena, Hargreaves, Patrick, Fraidling, Johannes, Ducret, Axel, Hartman, Katharina, Looney, Cary M, Bertinetti-Lapatki, Cristina, Rohr, Olivier, Hickling, Timothy P, Kraft, Thomas E, Marban-Doran, Céline

“…Immunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development,…”
Get full text

Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity by Siegel, Michel, Bolender, Anna-Lena, Ducret, Axel, Fraidling, Johannes, Hartman, Katharina, Looney, Cary M, Rohr, Olivier, Hickling, Timothy P, Kettenberger, Hubert, Lechmann, Martin, Marban-Doran, Céline, Kraft, Thomas E

“…Immunogenicity, the unwanted immune response triggered by therapeutic antibodies, poses significant challenges in biotherapeutic development. This response can…”
Get full text

Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes by Hartman, Katharina, Steiner, Guido, Siegel, Michel, Looney, Cary M, Hickling, Timothy P, Bray-French, Katharine, Springer, Sebastian, Marban-Doran, Céline, Ducret, Axel

“…A critical step in the immunogenicity cascade is attributed to human leukocyte antigen (HLA) II presentation triggering T cell immune responses. The liquid…”
Get full text

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients by Looney, Cary M., Schroeder, Aaron, Tavares, Erica, Garg, Jay, Schindler, Thomas, Vincenti, Flavio, Redfield, Robert R., Jordan, Stanley C., Busque, Stephan, Woodle, E. Steve, Khan, Jared, Eastham, Jeffrey, Micallef, Sandrine, Austin, Cary D., Morimoto, Alyssa

“…The THEORY study evaluated the effects of single and multiple doses of obinutuzumab, a type 2 anti-CD20 antibody that induces antibody-dependent cell-mediated…”
Get full text

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial by Furie, Richard A, Aroca, Gustavo, Cascino, Matthew D, Garg, Jay P, Rovin, Brad H, Alvarez, Analia, Fragoso-Loyo, Hilda, Zuta-Santillan, Elizabeth, Schindler, Thomas, Brunetta, Paul, Looney, Cary M, Hassan, Imran, Malvar, Ana

“…Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared…”
Get more information

Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease by Keir, Mary E., Fuh, Franklin, Ichikawa, Ryan, Acres, Meghan, Hackney, Jason A., Hulme, Gillian, Carey, Christopher D., Palmer, Jeremy, Jones, Claire J., Long, Anna K., Jiang, Jenny, Klabunde, Sha, Mansfield, John C., Looney, Cary M., Faubion, William A., Filby, Andrew, Kirby, John A., McBride, Jacqueline, Lamb, Christopher A.

“…Abstract Targeting interactions between α4β7 integrin and endothelial adhesion molecule MAdCAM-1 to inhibit lymphocyte migration to the gastrointestinal tract…”
Get full text

Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell–depleting agents by Looney, Cary M., Strauli, Nicolas, Cascino, Matthew D., Garma, Hailey, Schroeder, Aaron V., Takahashi, Chikara, O'Gorman, William, Green, Cherie, Herman, Ann E.

“…Targeted B-cell depletion is a useful therapy for many diseases, including autoimmune disorders and certain cancers. We developed a sensitive blood B-cell…”
Get full text

O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis by Furie, Richard A, Tas, Sander W, Malvar, Ana, Looney, Cary M, Raghu, Harini, Anania, Veronica G, Mao, Ashley, Schindler, Thomas, Martins, Elsa, Ross Terres, Jorge A, Vital, Edward M

“…ObjectiveTo investigate changes in peripheral B cells, B-cell subsets and biomarkers in NOBILITY.MethodsIn the randomized Phase II NOBILITY trial…”
Get full text